uk-dgm MCQ (SBA): Peak-Dose Dyskinesia in Parkinson's Disease

Instant feedback + full explanation. One question, done properly.

EasyParkinson's Disease & Movement DisordersPeak-Dose Dyskinesia in Parkinson's Diseaseuk-dgm

A 74-year-old man with Parkinson's disease has been stable on Co-careldopa 25/100 QDS for 4 years. He now develops involuntary writhing movements of his limbs and trunk that occur at peak medication effect, approximately 1-2 hours after each dose. What are these movements called?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.

uk-dgm MCQ: Peak-Dose Dyskinesia in Parkinson's Disease — Answer & Exp